Profit before exceptional items and tax increased 47.75% YoY to Rs 246.44 crore in Q4 FY26. Exceptional items stood at Rs 15.91 crore during the quarter.

EBITDA stood at Rs 352.1 crore in Q4 FY26, registering the growth of 40%, compared with Rs 252.4 crore in Q4 FY25.EBITDA margin improved to 24% in Q4 FY26 as against 21% in Q4 FY25.

Revenue from operations in Q4 FY26 was driven by finished dosages (FD) at 73%, followed by active pharmaceutical ingredients (API) at 13%, pharmaceutical formulation intermediates (PFI) at 9%, and peptide/CDMO at 5%.

On a full-year basis, the company’s consolidated net profit climbed 18.65% to Rs 595.02 crore on 19.73% increase in revenue from operations to Rs 5365.64 crore in FY26 over FY25.

Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.”

Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).